- Home
- MESO vs JANX Comparison
MESO vs JANX Comparison
Compare MESO & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MESO
- JANX
- Stock Information
- Founded
- MESO 2004
- JANX 2017
- Country
- MESO Australia
- JANX United States
- Employees
- MESO N/A
- JANX N/A
- Industry
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- MESO Health Care
- JANX Health Care
- Exchange
- MESO Nasdaq
- JANX Nasdaq
- Market Cap
- MESO 1.3B
- JANX 1.4B
- IPO Year
- MESO N/A
- JANX 2021
- Fundamental
- Price
- MESO $14.82
- JANX $24.05
- Analyst Decision
- MESO Buy
- JANX Strong Buy
- Analyst Count
- MESO 3
- JANX 10
- Target Price
- MESO $18.00
- JANX $79.50
- AVG Volume (30 Days)
- MESO 230.7K
- JANX 638.7K
- Earning Date
- MESO 08-28-2025
- JANX 11-05-2025
- Dividend Yield
- MESO N/A
- JANX N/A
- EPS Growth
- MESO N/A
- JANX N/A
- EPS
- MESO N/A
- JANX N/A
- Revenue
- MESO $17,198,000.00
- JANX $439,000.00
- Revenue This Year
- MESO $293.59
- JANX N/A
- Revenue Next Year
- MESO $218.64
- JANX $130.50
- P/E Ratio
- MESO N/A
- JANX N/A
- Revenue Growth
- MESO 191.39
- JANX N/A
- 52 Week Low
- MESO $6.00
- JANX $21.97
- 52 Week High
- MESO $22.00
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- MESO 50.33
- JANX 49.56
- Support Level
- MESO $12.66
- JANX $23.62
- Resistance Level
- MESO $15.67
- JANX $25.35
- Average True Range (ATR)
- MESO 0.45
- JANX 1.16
- MACD
- MESO -0.00
- JANX 0.15
- Stochastic Oscillator
- MESO 59.83
- JANX 51.57
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.